Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Wajeeh Khan

Intellia Therapeutics Pops on CRISPR Trial Success. Does That Make NTLA Stock a Buy?

Intellia Therapeutics (NTLA) shares charged up on April 27 after the company announced landmark Phase 3 results for its hereditary angioedema (HAE) candidate. This milestone represents the first-ever global Phase 3 data for an in vivo CRISPR therapy, proving the technology is clinically viable. 

Intellia Therapeutics stock has been a lucrative investment in 2026, currently up more than 50% versus the start of this year. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.